Ongoing genomic surveillance shows no new SARS-CoV-2 variants of concern designated by WHO or ECDC through mid-2026, even as lineages such as BA.3.2 (Cicada) and XFG subvariants circulated and reached notable shares in some regions during late 2025 and early 2026. These strains exhibited immune-escape mutations yet produced no measurable rise in overall severity, hospitalizations, or public-health impact relative to prior Omicron descendants. With only months remaining until 2027 and low global COVID-19 activity, the absence of rapid escalation to VOC status under established criteria underpins the 91.5% trader consensus on “No.” Continued monitoring could still surface shifts, though recent patterns indicate limited probability within the timeframe.